Ivabradine in patients with acute ST-elevation myocardial infarction: a meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Elevated resting heart rate (HR) predicts poor outcomes in patients with coronary artery disease. Ivabradine has been recommended as a second-line anti-anginal agent in chronic coronary syndrome, while there are no clear indications for acute ST-elevation myocardial infarction (STEMI).

Results

We systematically searched PubMed, Medline, EMBASE, Clinical Trials.gov, and the Cochrane Central Register of Controlled Trials with search terms Ivabradine and Acute myocardial infarction. There are two study outcomes from this study: therapeutic and safety effects. Therapeutic effects include the efficacy of Ivabradine on HR, all-cause mortality, heart failure incidence, left ventricular function and remodeling. Safety effects include troponin levels and ischemic events (r

SUBMITTER: Sasmita BR 

PROVIDER: S-EPMC10079792 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature